Laboratory of Molecular Oncology, Henan Collaborative Innovation Center of Molecular Diagnosis and Laboratory Medicine, School of laboratory Medicine, Xinxiang Medical University, Xinxiang, China.
Henan Key Laboratory of immunology and targeted therapy, Xinxiang Medical University, Xinxiang, China.
J Cell Mol Med. 2018 Sep;22(9):4161-4170. doi: 10.1111/jcmm.13694. Epub 2018 Jul 5.
Oestrogen receptor ɑ (ERɑ) is overexpressed in two-thirds of all breast cancers and involves in development and breast cancer progression. Although ERɑ-positive breast cancer could be effective treated by endocrine therapy, the endocrine resistance is still an urgent clinical problem. Thus, further understanding of the underlying mechanisms ERɑ signalling is critical in dealing with endocrine resistance in breast cancer patients. MCF-7 and T47D breast cancer cell lines are used to carry out the molecular biological experiments. Western blot is used to assess the relative protein level of ERɑ, RNF168 and actin. Real-time PCR is used the measure the relative ERɑ-related gene mRNA level. Luciferase assay is used to measure the relative ERɑ signalling activity. Chromatin immunoprecipitation is used to measure the RNF168 binding affinity to ERɑ promoter regions. WST assay and flow cytometry are used to measure the cell proliferation capacity. We use Student's t test and one-way ANOVA test for statistical data analysis. Here, we report an important role in ERɑ-positive breast cancer cells for RNF168 protein in supporting cell proliferation by driving the transcription of ERɑ. RNF168 is highly expressed in breast cancer samples, compared with normal breast tissue. In patients with breast cancer, RNF168 expression level is correlated with poor endocrine treatment outcome. Depletion of RNF168 causes decreased cell proliferation in MCF-7 and T47D cells. Besides, depletion RNF168 reduced mRNA level of ERɑ and its target genes, such as PS2 and GREB1. Chromatin immunoprecipitation revealed that ERɑ transcription is associated with RNF168 recruitment to ERɑ promoter region, suggesting that transcriptional regulation is one mechanism by which RNF168 regulates ERɑ mRNA level and ERɑ signalling in breast cancer cells. RNF168 is required for ERɑ-positive breast cancer cell proliferation and facilitate ERɑ signalling activity possibly through promoting transcription of ERɑ.
雌激素受体 α(ERα)在三分之二的所有乳腺癌中过表达,并参与乳腺癌的发生和发展。尽管 ERα 阳性乳腺癌可以通过内分泌治疗有效治疗,但内分泌抵抗仍然是一个迫切的临床问题。因此,进一步了解 ERα 信号的潜在机制对于应对乳腺癌患者的内分泌抵抗至关重要。MCF-7 和 T47D 乳腺癌细胞系用于进行分子生物学实验。使用 Western blot 评估 ERα、RNF168 和肌动蛋白的相对蛋白水平。使用实时 PCR 测量相对的 ERα 相关基因 mRNA 水平。使用荧光素酶测定测量相对的 ERα 信号活性。使用染色质免疫沉淀测定 RNF168 与 ERα 启动子区域的结合亲和力。WST 测定和流式细胞术用于测量细胞增殖能力。我们使用 Student's t 检验和单因素方差分析进行统计数据分析。在这里,我们报告了 RNF168 蛋白在支持 ERα 阳性乳腺癌细胞增殖中的重要作用,通过驱动 ERα 的转录。与正常乳腺组织相比,RNF168 在乳腺癌样本中高表达。在乳腺癌患者中,RNF168 的表达水平与内分泌治疗效果差相关。RNF168 的耗竭导致 MCF-7 和 T47D 细胞的增殖减少。此外,RNF168 的耗竭降低了 ERα 及其靶基因(如 PS2 和 GREB1)的 mRNA 水平。染色质免疫沉淀显示 ERα 转录与 RNF168 募集到 ERα 启动子区域相关,表明转录调控是 RNF168 调节乳腺癌细胞中 ERα mRNA 水平和 ERα 信号的一种机制。RNF168 是 ERα 阳性乳腺癌细胞增殖所必需的,并通过促进 ERα 的转录来促进 ERα 信号活性。